ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0907

Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)

Laura Coates1, Dafna Gladman2, Filip Van den Bosch3, Philip Helliwell4, Anna Rychlewska-Hańczewska5, Mykola Stanislavchuk6, Leen Gilles7, Lien Gheyle7, Ke Liu8, Mona Trivedi8, Muhsen Alani9, Robin Besuyen10 and Philip Mease11, 1University of Oxford, Oxford, United Kingdom, 2Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 3Ghent University Hospital, Ghent, Belgium, 4Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 5Ai Centrum Medyczne, Poznań, Poland, 6National Pirogov Memorial Medical University, Vinnytsya, Ukraine, 7Galapagos NV, Mechelen, Belgium, 8Gilead Sciences, Inc., Foster City, CA, 9Gilead Sciences, Inc. and University of Washington, Foster City, CA, 10Galapagos BV, Leiden, Netherlands, 11Seattle Rheumatology Associates, P.L.L.C., Seattle, WA

Meeting: ACR Convergence 2020

Keywords: Disease Activity, Psoriatic arthritis, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: EQUATOR (NCT03101670) was a randomized, 16-week, Phase 2, multicenter, double-blind, placebo (PBO)‑controlled trial of filgotinib (FIL) in patients with active PsA ( Mease P, et al. Lancet 2018;392:2367–77) . In EQUATOR, FIL was well tolerated and was efficacious vs PBO for the primary endpoint of Week 16 ACR20 response. Patients completing EQUATOR could join an ongoing 304‑week OLE (EQUATOR2; NCT03320876). We report the findings of an interim analysis of EQUATOR2 at Week 100. Primary and secondary objectives were to assess safety/tolerability and efficacy, respectively.

Methods: In EQUATOR, patients with active moderate-to-severe  PsA (≥5 swollen joints and ≥5 tender joints, fulfilling Classification for PsA [CASPAR] criteria) were randomized 1:1 to receive oral FIL 200 mg or PBO once daily (QD) for 16 weeks. At Week 16, patients could continue into the OLE, receiving FIL 200 mg QD. For this interim analysis, patients were followed for efficacy until the last patient completed their Week 100 visit; safety data were collected up to April 8, 2020. Efficacy measures included minimal disease activity (MDA; meeting 5/7 MDA criteria), MDA/very low disease activity (VLDA; meeting 7/7 MDA criteria), Psoriatic Arthritis Disease Activity Score (PASDAS) low disease activity (score ≤3.2) and VLDA (score ≤1.9), ACR20/50/70, and Psoriasis Area and Severity Index (PASI) 75/90/100. The number and proportion of patients achieving each endpoint were calculated using observed case (OC) and non-responder imputation (NRI) approaches. Adverse events (AEs) per 100 patient-years of exposure (from first exposure to FIL) are summarized.

Results: Of 131 randomized patients, 124 (95%) completed EQUATOR and 122 (93%) were enrolled in the OLE, of whom 104 patients (85%) remained in the study at Week 100. Safety and tolerability were similar at Week 100 to a previous analysis conducted at Week 52 (Table 1). No unexpected safety issues were identified. By Week 100, 1 death (bilateral pneumonia, leading to toxic shock with multi-organ failure ) and 1 adjudicated major adverse cardiac event had occurred (both prior to Week 52). Five additional serious treatment-emergent AEs occurred from Week 52 to 100, including 1 serious infection (COVID-19). No deep vein thromboses or pulmonary embolisms occurred up to Week 100. Efficacy was sustained at Week 100 (Table 2). The response rate at Week 100 for all patients (regardless of original randomization to PBO or FIL) was 31.3% for MDA (NRI; 42.3% for OC; Figure), and 60.3%/43.5%/29.0% for ACR20/50/70 (NRI; 81.4%/58.8%/39.2% for OC). Of 15 patients originally randomized to FIL who were MDA responders at Week 16, 73.3% also had an MDA response at Week 100 (NRI). Sustained responses were observed at ≥3 consecutive visits (each of which was 12 weeks apart) for MDA in 34.4% of patients (NRI).

Conclusion: This interim analysis of long-term extension data from the PsA EQUATOR2 study found FIL 200 mg QD to be generally well tolerated up to Week 100 with a safety profile comparable to that seen up to Week 52. Response rates at Week 100 to FIL 200 mg QD were stable and comparable to those reported at Week 52. In most patients who were MDA responders at Week 16, responses were also seen at Week 100.

Table 1. Overview of safety with FIL 200 mg QD at Week 52 and Week 100 of the EQUATOR2 OLE. *Defined as Grade ≥3. †Excludes deaths. AE, adverse event; FIL, filgotinib; OLE, open-label extension; PYE, patient-years of exposure; QD, once daily; RTI, respiratory tract infection; TEAE, treatment-emergent adverse event

Table 2. Responders at Week 100 of the OLE (NRI). *Defined as meeting 5 out of 7 of the MDA criteria. †Defined as meeting 7 out of 7 of the MDA criteria. ‡Defined as a PASDAS score of ≤3.2. §Defined as a PASDAS score of ≤1.9. ¶PASI was only measured in patients with ≥3% of their body surface area affected by psoriasis. ACR, American College Rheumatology; LDA, low disease activity; MDA, minimal disease activity; NRI, non-responder imputation; OLE, open-label extension; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI, Psoriasis Area and Severity Index; VLDA, very low disease activity

Figure 1. MDA response rate over time (NRI). BL, baseline; MDA, minimal disease activity; NRI, non-responder imputation; OLE, open-label extension; W, Week


Disclosure: L. Coates, AbbVie, 2, 5, 8, Celgene, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, Amgen Inc., 5, 8, Gilead, 5, 8, Janssen, 5, 8, UCB Pharma, 5, 8, Eli Lilly, 2, 5, 8, Biogen, 8, Medac, 8, Boehringer Ingelheim, 5, MSD, 5; D. Gladman, AbbVie, 2, 5, Amgen, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5, Bristol-Myers Squibb, 5, Gilead, 5, Galapagos, 5, Celgene, 2, 5, Eli Lilly, 2, 5; F. Van den Bosch, AbbVie, 5, 8, Celgene, 5, 8, Eli Lilly, 5, 8, Galapagos, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB, 5, 8, Gilead, 5, Merck, 5, 8; P. Helliwell, AbbVie, 2, 8, Janssen, 2, Pfizer Inc, 8, Celgene, 8, Galapagos, 8, Amgen, 8, Novartis, 2, UCB, 8; A. Rychlewska-Hańczewska, Galapagos, 2, Gilead Sciences, 2; M. Stanislavchuk, AstraZeneca, 2, Celltrion, 2, Eli Lilly, 2, Galapagos, 2, Genentech, 2, GlaxoSmithKline, 2, Human Genome, 2, MedImmune, 2, Pfizer, 2, Roche, 2, UCB, 2; L. Gilles, Galapagos, 3; L. Gheyle, Galapagos, 1, 3; K. Liu, Gilead Sciences, 1, 3; M. Trivedi, Gilead Sciences, 1, 3, Amgen, 1; M. Alani, Gilead Sciences, 3; R. Besuyen, Galapagos, 1, 3; P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5.

To cite this abstract in AMA style:

Coates L, Gladman D, Van den Bosch F, Helliwell P, Rychlewska-Hańczewska A, Stanislavchuk M, Gilles L, Gheyle L, Liu K, Trivedi M, Alani M, Besuyen R, Mease P. Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA) [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/long-term-outcomes-with-filgotinib-an-oral-selective-janus-kinase-1-inhibitor-100-week-data-from-an-open-label-extension-ole-study-in-patients-with-active-psoriatic-arthritis-psa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-outcomes-with-filgotinib-an-oral-selective-janus-kinase-1-inhibitor-100-week-data-from-an-open-label-extension-ole-study-in-patients-with-active-psoriatic-arthritis-psa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology